Nat Med:透明细胞肾细胞肿瘤中体细胞变异和免疫浸润互作调控对PD-1阻断的响应

2020-05-31 AlexYang MedSci原创

PD-1阻断革新了对晚期透明细胞肾细胞癌(ccRCC)的治疗,但是PD-1响应的驱使因子和抵抗因子仍旧不完全清晰。

PD-1阻断革新了对晚期透明细胞肾细胞癌(ccRCC)的治疗,但是PD-1响应的驱使因子和抵抗因子仍旧不完全清晰。

最近,有研究人员分析了来自PD-1阻断治疗前瞻性临床试验的晚期ccRCC患者的592份肿瘤,使用了全外显子组和RNA测序分析,并整合了免疫荧光分析,从而揭示治疗响应的免疫基因组决定因子。尽管传统的基因组标记(比如肿瘤变异压力和新抗原负荷)和CD8+细胞浸润的程度与临床响应没有关系,研究人员发现大量的与PD-1阻断响应或者抵抗相关的染色体改变。这些晚期的ccRCC肿瘤均为高度CD8+T细胞浸润,只有27%的具有非浸润表型。

最后,研究人员指出,他们的研究阐释了与非浸润性肿瘤相比,浸润性肿瘤缺乏有利的PBRM1突变,并富集了不利的9p21.3染色体损失。同时揭示了免疫表型与体细胞变异是怎样互作来影响治疗效果的。

原始出处:

David A. Braun, Yue Hou, Ziad Bakouny et al. Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma. Nat Med. 29 May 2020

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1797907, encodeId=5dcb1e979071c, content=<a href='/topic/show?id=bbd62410e51' target=_blank style='color:#2F92EE;'>#互作调控#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24107, encryptionId=bbd62410e51, topicName=互作调控)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba58436, createdName=马龙, createdTime=Mon Mar 22 07:23:40 CST 2021, time=2021-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710237, encodeId=b18c1e1023728, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Mon Jun 15 15:23:40 CST 2020, time=2020-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1786907, encodeId=5ea61e86907c6, content=<a href='/topic/show?id=05481391901' target=_blank style='color:#2F92EE;'>#PD-1阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13919, encryptionId=05481391901, topicName=PD-1阻断)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd34186, createdName=wshxjq, createdTime=Sun Oct 11 23:23:40 CST 2020, time=2020-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1680039, encodeId=9ee116800392c, content=<a href='/topic/show?id=ab358265095' target=_blank style='color:#2F92EE;'>#肾细胞肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82650, encryptionId=ab358265095, topicName=肾细胞肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b19d27833533, createdName=isabellayj, createdTime=Thu Nov 12 09:23:40 CST 2020, time=2020-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884357, encodeId=cd55188435efa, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Jul 21 07:23:40 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342696, encodeId=ba9d134269642, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Tue Jun 02 04:23:40 CST 2020, time=2020-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1438352, encodeId=e5cc143835277, content=<a href='/topic/show?id=c8a526638f6' target=_blank style='color:#2F92EE;'>#体细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26638, encryptionId=c8a526638f6, topicName=体细胞)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Tue Jun 02 04:23:40 CST 2020, time=2020-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471661, encodeId=b44614e16618a, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Tue Jun 02 04:23:40 CST 2020, time=2020-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557311, encodeId=c7b8155e311bc, content=<a href='/topic/show?id=f048290e85c' target=_blank style='color:#2F92EE;'>#免疫浸润#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29078, encryptionId=f048290e85c, topicName=免疫浸润)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=769d14903231, createdName=cenghis, createdTime=Tue Jun 02 04:23:40 CST 2020, time=2020-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610515, encodeId=fd54161051519, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Jun 02 04:23:40 CST 2020, time=2020-06-02, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1797907, encodeId=5dcb1e979071c, content=<a href='/topic/show?id=bbd62410e51' target=_blank style='color:#2F92EE;'>#互作调控#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24107, encryptionId=bbd62410e51, topicName=互作调控)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba58436, createdName=马龙, createdTime=Mon Mar 22 07:23:40 CST 2021, time=2021-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710237, encodeId=b18c1e1023728, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Mon Jun 15 15:23:40 CST 2020, time=2020-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1786907, encodeId=5ea61e86907c6, content=<a href='/topic/show?id=05481391901' target=_blank style='color:#2F92EE;'>#PD-1阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13919, encryptionId=05481391901, topicName=PD-1阻断)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd34186, createdName=wshxjq, createdTime=Sun Oct 11 23:23:40 CST 2020, time=2020-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1680039, encodeId=9ee116800392c, content=<a href='/topic/show?id=ab358265095' target=_blank style='color:#2F92EE;'>#肾细胞肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82650, encryptionId=ab358265095, topicName=肾细胞肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b19d27833533, createdName=isabellayj, createdTime=Thu Nov 12 09:23:40 CST 2020, time=2020-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884357, encodeId=cd55188435efa, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Jul 21 07:23:40 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342696, encodeId=ba9d134269642, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Tue Jun 02 04:23:40 CST 2020, time=2020-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1438352, encodeId=e5cc143835277, content=<a href='/topic/show?id=c8a526638f6' target=_blank style='color:#2F92EE;'>#体细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26638, encryptionId=c8a526638f6, topicName=体细胞)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Tue Jun 02 04:23:40 CST 2020, time=2020-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471661, encodeId=b44614e16618a, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Tue Jun 02 04:23:40 CST 2020, time=2020-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557311, encodeId=c7b8155e311bc, content=<a href='/topic/show?id=f048290e85c' target=_blank style='color:#2F92EE;'>#免疫浸润#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29078, encryptionId=f048290e85c, topicName=免疫浸润)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=769d14903231, createdName=cenghis, createdTime=Tue Jun 02 04:23:40 CST 2020, time=2020-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610515, encodeId=fd54161051519, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Jun 02 04:23:40 CST 2020, time=2020-06-02, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1797907, encodeId=5dcb1e979071c, content=<a href='/topic/show?id=bbd62410e51' target=_blank style='color:#2F92EE;'>#互作调控#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24107, encryptionId=bbd62410e51, topicName=互作调控)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba58436, createdName=马龙, createdTime=Mon Mar 22 07:23:40 CST 2021, time=2021-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710237, encodeId=b18c1e1023728, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Mon Jun 15 15:23:40 CST 2020, time=2020-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1786907, encodeId=5ea61e86907c6, content=<a href='/topic/show?id=05481391901' target=_blank style='color:#2F92EE;'>#PD-1阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13919, encryptionId=05481391901, topicName=PD-1阻断)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd34186, createdName=wshxjq, createdTime=Sun Oct 11 23:23:40 CST 2020, time=2020-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1680039, encodeId=9ee116800392c, content=<a href='/topic/show?id=ab358265095' target=_blank style='color:#2F92EE;'>#肾细胞肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82650, encryptionId=ab358265095, topicName=肾细胞肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b19d27833533, createdName=isabellayj, createdTime=Thu Nov 12 09:23:40 CST 2020, time=2020-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884357, encodeId=cd55188435efa, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Jul 21 07:23:40 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342696, encodeId=ba9d134269642, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Tue Jun 02 04:23:40 CST 2020, time=2020-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1438352, encodeId=e5cc143835277, content=<a href='/topic/show?id=c8a526638f6' target=_blank style='color:#2F92EE;'>#体细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26638, encryptionId=c8a526638f6, topicName=体细胞)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Tue Jun 02 04:23:40 CST 2020, time=2020-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471661, encodeId=b44614e16618a, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Tue Jun 02 04:23:40 CST 2020, time=2020-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557311, encodeId=c7b8155e311bc, content=<a href='/topic/show?id=f048290e85c' target=_blank style='color:#2F92EE;'>#免疫浸润#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29078, encryptionId=f048290e85c, topicName=免疫浸润)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=769d14903231, createdName=cenghis, createdTime=Tue Jun 02 04:23:40 CST 2020, time=2020-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610515, encodeId=fd54161051519, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Jun 02 04:23:40 CST 2020, time=2020-06-02, status=1, ipAttribution=)]
    2020-10-11 wshxjq
  4. [GetPortalCommentsPageByObjectIdResponse(id=1797907, encodeId=5dcb1e979071c, content=<a href='/topic/show?id=bbd62410e51' target=_blank style='color:#2F92EE;'>#互作调控#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24107, encryptionId=bbd62410e51, topicName=互作调控)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba58436, createdName=马龙, createdTime=Mon Mar 22 07:23:40 CST 2021, time=2021-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710237, encodeId=b18c1e1023728, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Mon Jun 15 15:23:40 CST 2020, time=2020-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1786907, encodeId=5ea61e86907c6, content=<a href='/topic/show?id=05481391901' target=_blank style='color:#2F92EE;'>#PD-1阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13919, encryptionId=05481391901, topicName=PD-1阻断)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd34186, createdName=wshxjq, createdTime=Sun Oct 11 23:23:40 CST 2020, time=2020-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1680039, encodeId=9ee116800392c, content=<a href='/topic/show?id=ab358265095' target=_blank style='color:#2F92EE;'>#肾细胞肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82650, encryptionId=ab358265095, topicName=肾细胞肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b19d27833533, createdName=isabellayj, createdTime=Thu Nov 12 09:23:40 CST 2020, time=2020-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884357, encodeId=cd55188435efa, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Jul 21 07:23:40 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342696, encodeId=ba9d134269642, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Tue Jun 02 04:23:40 CST 2020, time=2020-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1438352, encodeId=e5cc143835277, content=<a href='/topic/show?id=c8a526638f6' target=_blank style='color:#2F92EE;'>#体细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26638, encryptionId=c8a526638f6, topicName=体细胞)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Tue Jun 02 04:23:40 CST 2020, time=2020-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471661, encodeId=b44614e16618a, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Tue Jun 02 04:23:40 CST 2020, time=2020-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557311, encodeId=c7b8155e311bc, content=<a href='/topic/show?id=f048290e85c' target=_blank style='color:#2F92EE;'>#免疫浸润#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29078, encryptionId=f048290e85c, topicName=免疫浸润)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=769d14903231, createdName=cenghis, createdTime=Tue Jun 02 04:23:40 CST 2020, time=2020-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610515, encodeId=fd54161051519, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Jun 02 04:23:40 CST 2020, time=2020-06-02, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1797907, encodeId=5dcb1e979071c, content=<a href='/topic/show?id=bbd62410e51' target=_blank style='color:#2F92EE;'>#互作调控#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24107, encryptionId=bbd62410e51, topicName=互作调控)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba58436, createdName=马龙, createdTime=Mon Mar 22 07:23:40 CST 2021, time=2021-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710237, encodeId=b18c1e1023728, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Mon Jun 15 15:23:40 CST 2020, time=2020-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1786907, encodeId=5ea61e86907c6, content=<a href='/topic/show?id=05481391901' target=_blank style='color:#2F92EE;'>#PD-1阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13919, encryptionId=05481391901, topicName=PD-1阻断)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd34186, createdName=wshxjq, createdTime=Sun Oct 11 23:23:40 CST 2020, time=2020-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1680039, encodeId=9ee116800392c, content=<a href='/topic/show?id=ab358265095' target=_blank style='color:#2F92EE;'>#肾细胞肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82650, encryptionId=ab358265095, topicName=肾细胞肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b19d27833533, createdName=isabellayj, createdTime=Thu Nov 12 09:23:40 CST 2020, time=2020-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884357, encodeId=cd55188435efa, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Jul 21 07:23:40 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342696, encodeId=ba9d134269642, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Tue Jun 02 04:23:40 CST 2020, time=2020-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1438352, encodeId=e5cc143835277, content=<a href='/topic/show?id=c8a526638f6' target=_blank style='color:#2F92EE;'>#体细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26638, encryptionId=c8a526638f6, topicName=体细胞)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Tue Jun 02 04:23:40 CST 2020, time=2020-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471661, encodeId=b44614e16618a, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Tue Jun 02 04:23:40 CST 2020, time=2020-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557311, encodeId=c7b8155e311bc, content=<a href='/topic/show?id=f048290e85c' target=_blank style='color:#2F92EE;'>#免疫浸润#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29078, encryptionId=f048290e85c, topicName=免疫浸润)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=769d14903231, createdName=cenghis, createdTime=Tue Jun 02 04:23:40 CST 2020, time=2020-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610515, encodeId=fd54161051519, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Jun 02 04:23:40 CST 2020, time=2020-06-02, status=1, ipAttribution=)]
    2020-07-21 liye789132251
  6. [GetPortalCommentsPageByObjectIdResponse(id=1797907, encodeId=5dcb1e979071c, content=<a href='/topic/show?id=bbd62410e51' target=_blank style='color:#2F92EE;'>#互作调控#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24107, encryptionId=bbd62410e51, topicName=互作调控)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba58436, createdName=马龙, createdTime=Mon Mar 22 07:23:40 CST 2021, time=2021-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710237, encodeId=b18c1e1023728, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Mon Jun 15 15:23:40 CST 2020, time=2020-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1786907, encodeId=5ea61e86907c6, content=<a href='/topic/show?id=05481391901' target=_blank style='color:#2F92EE;'>#PD-1阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13919, encryptionId=05481391901, topicName=PD-1阻断)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd34186, createdName=wshxjq, createdTime=Sun Oct 11 23:23:40 CST 2020, time=2020-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1680039, encodeId=9ee116800392c, content=<a href='/topic/show?id=ab358265095' target=_blank style='color:#2F92EE;'>#肾细胞肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82650, encryptionId=ab358265095, topicName=肾细胞肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b19d27833533, createdName=isabellayj, createdTime=Thu Nov 12 09:23:40 CST 2020, time=2020-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884357, encodeId=cd55188435efa, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Jul 21 07:23:40 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342696, encodeId=ba9d134269642, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Tue Jun 02 04:23:40 CST 2020, time=2020-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1438352, encodeId=e5cc143835277, content=<a href='/topic/show?id=c8a526638f6' target=_blank style='color:#2F92EE;'>#体细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26638, encryptionId=c8a526638f6, topicName=体细胞)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Tue Jun 02 04:23:40 CST 2020, time=2020-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471661, encodeId=b44614e16618a, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Tue Jun 02 04:23:40 CST 2020, time=2020-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557311, encodeId=c7b8155e311bc, content=<a href='/topic/show?id=f048290e85c' target=_blank style='color:#2F92EE;'>#免疫浸润#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29078, encryptionId=f048290e85c, topicName=免疫浸润)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=769d14903231, createdName=cenghis, createdTime=Tue Jun 02 04:23:40 CST 2020, time=2020-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610515, encodeId=fd54161051519, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Jun 02 04:23:40 CST 2020, time=2020-06-02, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1797907, encodeId=5dcb1e979071c, content=<a href='/topic/show?id=bbd62410e51' target=_blank style='color:#2F92EE;'>#互作调控#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24107, encryptionId=bbd62410e51, topicName=互作调控)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba58436, createdName=马龙, createdTime=Mon Mar 22 07:23:40 CST 2021, time=2021-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710237, encodeId=b18c1e1023728, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Mon Jun 15 15:23:40 CST 2020, time=2020-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1786907, encodeId=5ea61e86907c6, content=<a href='/topic/show?id=05481391901' target=_blank style='color:#2F92EE;'>#PD-1阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13919, encryptionId=05481391901, topicName=PD-1阻断)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd34186, createdName=wshxjq, createdTime=Sun Oct 11 23:23:40 CST 2020, time=2020-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1680039, encodeId=9ee116800392c, content=<a href='/topic/show?id=ab358265095' target=_blank style='color:#2F92EE;'>#肾细胞肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82650, encryptionId=ab358265095, topicName=肾细胞肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b19d27833533, createdName=isabellayj, createdTime=Thu Nov 12 09:23:40 CST 2020, time=2020-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884357, encodeId=cd55188435efa, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Jul 21 07:23:40 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342696, encodeId=ba9d134269642, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Tue Jun 02 04:23:40 CST 2020, time=2020-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1438352, encodeId=e5cc143835277, content=<a href='/topic/show?id=c8a526638f6' target=_blank style='color:#2F92EE;'>#体细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26638, encryptionId=c8a526638f6, topicName=体细胞)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Tue Jun 02 04:23:40 CST 2020, time=2020-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471661, encodeId=b44614e16618a, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Tue Jun 02 04:23:40 CST 2020, time=2020-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557311, encodeId=c7b8155e311bc, content=<a href='/topic/show?id=f048290e85c' target=_blank style='color:#2F92EE;'>#免疫浸润#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29078, encryptionId=f048290e85c, topicName=免疫浸润)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=769d14903231, createdName=cenghis, createdTime=Tue Jun 02 04:23:40 CST 2020, time=2020-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610515, encodeId=fd54161051519, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Jun 02 04:23:40 CST 2020, time=2020-06-02, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1797907, encodeId=5dcb1e979071c, content=<a href='/topic/show?id=bbd62410e51' target=_blank style='color:#2F92EE;'>#互作调控#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24107, encryptionId=bbd62410e51, topicName=互作调控)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba58436, createdName=马龙, createdTime=Mon Mar 22 07:23:40 CST 2021, time=2021-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710237, encodeId=b18c1e1023728, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Mon Jun 15 15:23:40 CST 2020, time=2020-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1786907, encodeId=5ea61e86907c6, content=<a href='/topic/show?id=05481391901' target=_blank style='color:#2F92EE;'>#PD-1阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13919, encryptionId=05481391901, topicName=PD-1阻断)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd34186, createdName=wshxjq, createdTime=Sun Oct 11 23:23:40 CST 2020, time=2020-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1680039, encodeId=9ee116800392c, content=<a href='/topic/show?id=ab358265095' target=_blank style='color:#2F92EE;'>#肾细胞肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82650, encryptionId=ab358265095, topicName=肾细胞肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b19d27833533, createdName=isabellayj, createdTime=Thu Nov 12 09:23:40 CST 2020, time=2020-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884357, encodeId=cd55188435efa, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Jul 21 07:23:40 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342696, encodeId=ba9d134269642, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Tue Jun 02 04:23:40 CST 2020, time=2020-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1438352, encodeId=e5cc143835277, content=<a href='/topic/show?id=c8a526638f6' target=_blank style='color:#2F92EE;'>#体细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26638, encryptionId=c8a526638f6, topicName=体细胞)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Tue Jun 02 04:23:40 CST 2020, time=2020-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471661, encodeId=b44614e16618a, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Tue Jun 02 04:23:40 CST 2020, time=2020-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557311, encodeId=c7b8155e311bc, content=<a href='/topic/show?id=f048290e85c' target=_blank style='color:#2F92EE;'>#免疫浸润#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29078, encryptionId=f048290e85c, topicName=免疫浸润)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=769d14903231, createdName=cenghis, createdTime=Tue Jun 02 04:23:40 CST 2020, time=2020-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610515, encodeId=fd54161051519, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Jun 02 04:23:40 CST 2020, time=2020-06-02, status=1, ipAttribution=)]
    2020-06-02 ylz8405
  9. [GetPortalCommentsPageByObjectIdResponse(id=1797907, encodeId=5dcb1e979071c, content=<a href='/topic/show?id=bbd62410e51' target=_blank style='color:#2F92EE;'>#互作调控#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24107, encryptionId=bbd62410e51, topicName=互作调控)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba58436, createdName=马龙, createdTime=Mon Mar 22 07:23:40 CST 2021, time=2021-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710237, encodeId=b18c1e1023728, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Mon Jun 15 15:23:40 CST 2020, time=2020-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1786907, encodeId=5ea61e86907c6, content=<a href='/topic/show?id=05481391901' target=_blank style='color:#2F92EE;'>#PD-1阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13919, encryptionId=05481391901, topicName=PD-1阻断)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd34186, createdName=wshxjq, createdTime=Sun Oct 11 23:23:40 CST 2020, time=2020-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1680039, encodeId=9ee116800392c, content=<a href='/topic/show?id=ab358265095' target=_blank style='color:#2F92EE;'>#肾细胞肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82650, encryptionId=ab358265095, topicName=肾细胞肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b19d27833533, createdName=isabellayj, createdTime=Thu Nov 12 09:23:40 CST 2020, time=2020-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884357, encodeId=cd55188435efa, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Jul 21 07:23:40 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342696, encodeId=ba9d134269642, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Tue Jun 02 04:23:40 CST 2020, time=2020-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1438352, encodeId=e5cc143835277, content=<a href='/topic/show?id=c8a526638f6' target=_blank style='color:#2F92EE;'>#体细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26638, encryptionId=c8a526638f6, topicName=体细胞)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Tue Jun 02 04:23:40 CST 2020, time=2020-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471661, encodeId=b44614e16618a, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Tue Jun 02 04:23:40 CST 2020, time=2020-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557311, encodeId=c7b8155e311bc, content=<a href='/topic/show?id=f048290e85c' target=_blank style='color:#2F92EE;'>#免疫浸润#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29078, encryptionId=f048290e85c, topicName=免疫浸润)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=769d14903231, createdName=cenghis, createdTime=Tue Jun 02 04:23:40 CST 2020, time=2020-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610515, encodeId=fd54161051519, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Jun 02 04:23:40 CST 2020, time=2020-06-02, status=1, ipAttribution=)]
  10. [GetPortalCommentsPageByObjectIdResponse(id=1797907, encodeId=5dcb1e979071c, content=<a href='/topic/show?id=bbd62410e51' target=_blank style='color:#2F92EE;'>#互作调控#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24107, encryptionId=bbd62410e51, topicName=互作调控)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba58436, createdName=马龙, createdTime=Mon Mar 22 07:23:40 CST 2021, time=2021-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710237, encodeId=b18c1e1023728, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Mon Jun 15 15:23:40 CST 2020, time=2020-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1786907, encodeId=5ea61e86907c6, content=<a href='/topic/show?id=05481391901' target=_blank style='color:#2F92EE;'>#PD-1阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13919, encryptionId=05481391901, topicName=PD-1阻断)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd34186, createdName=wshxjq, createdTime=Sun Oct 11 23:23:40 CST 2020, time=2020-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1680039, encodeId=9ee116800392c, content=<a href='/topic/show?id=ab358265095' target=_blank style='color:#2F92EE;'>#肾细胞肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82650, encryptionId=ab358265095, topicName=肾细胞肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b19d27833533, createdName=isabellayj, createdTime=Thu Nov 12 09:23:40 CST 2020, time=2020-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884357, encodeId=cd55188435efa, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Jul 21 07:23:40 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342696, encodeId=ba9d134269642, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Tue Jun 02 04:23:40 CST 2020, time=2020-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1438352, encodeId=e5cc143835277, content=<a href='/topic/show?id=c8a526638f6' target=_blank style='color:#2F92EE;'>#体细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26638, encryptionId=c8a526638f6, topicName=体细胞)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Tue Jun 02 04:23:40 CST 2020, time=2020-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471661, encodeId=b44614e16618a, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Tue Jun 02 04:23:40 CST 2020, time=2020-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557311, encodeId=c7b8155e311bc, content=<a href='/topic/show?id=f048290e85c' target=_blank style='color:#2F92EE;'>#免疫浸润#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29078, encryptionId=f048290e85c, topicName=免疫浸润)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=769d14903231, createdName=cenghis, createdTime=Tue Jun 02 04:23:40 CST 2020, time=2020-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610515, encodeId=fd54161051519, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Jun 02 04:23:40 CST 2020, time=2020-06-02, status=1, ipAttribution=)]

相关资讯

Sci Rep:肾肿瘤CD105−/CD44−细胞具有干细胞特性并能够在体内形成恶性肿瘤

透明细胞肾细胞肿瘤(ccRCC)是最常见肾癌。因ccRCC对化疗和放疗具有较强的抗性,其预后通常较差。许多研究表明癌症干细胞/肿瘤起始细胞(CSCs/TICs)与肿瘤的发展、疾病的恶化和入侵、转移以及

盘点:肾细胞癌进展盘点

肾细胞癌(简称肾癌)是泌尿系统中恶性程度较高的肿瘤,也是最常见的肿瘤之一,又称肾腺癌,占肾恶性肿瘤的80%~90%。据调查,肾细胞癌在我国泌尿生殖系统肿瘤中占第二位,仅次于膀胱肿瘤,占成人恶性肿瘤的2

盘点:肾病研究进展小结

肾细胞癌(简称肾癌)是泌尿系统中恶性程度较高的肿瘤,也是最常见的肿瘤之一,又称肾腺癌,占肾恶性肿瘤的80%~90%。据调查,肾细胞癌在我国泌尿生殖系统肿瘤中占第二位,仅次于膀胱肿瘤,占成人恶性肿瘤的2

Brit J Cancer:犬尿氨酸途径多点异常时肾癌的一个普遍特征

吲哚胺2,3-双加氧酶(IDO)是犬尿氨酸途径(KP)中的第一步,其在一些癌症中上调。由于其在肿瘤免疫逃避中具有作用,因此是一个很有前景的治疗靶标。然而,IDO抑制剂在后期临床试验中的失败对该策略也产

Sci Rep:肿瘤等级与肿瘤组织总功能障碍显著相关

评估CD8T细胞和CD4T细胞的表达的临床重要性是非常重要的,因为其在肿瘤靶向免疫响应中具有重要的网络。

Hypertension:高血压与肾癌风险的关系

与正常血压相比,高血压和高收缩压或舒张压与患肾癌的风险增加有关。